Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA has expanded approval of talazoparib (Talzenna) plus enzalutamide (Xtandi) to include patients with hormone-sensitive metastatic prostate cancer carrying HRR gene mutations — moving the PARP inhibitor combo into an earlier line of treatment. Previously approved only for castration-resistant disease in 2023, the expanded indication is backed by the TALAPRO-3 trial, which showed a 52% reduction in the risk of radiographic progression or death.
The FDA has expanded the approved use of talazoparib (Talzenna, Pfizer) combined with enzalutamide for patients with metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer who carry homologous recombination repair (HRR) gene mutations. Originally approved in 2023 for castration-resistant prostate cancer, this label expansion moves the PARP inhibitor combination into an earlier, hormone-sensitive disease setting — a stage where more patients may benefit from delaying progression.
The approval was supported by the phase 3 TALAPRO-3 trial, which demonstrated a striking improvement in radiographic progression-free survival. Pfizer described the move as an opportunity to intervene "at a critical stage" of the disease. Companion diagnostics — FoundationOne CDx and FoundationOne Liquid CDx — are used to identify eligible patients with HRR gene alterations.
By the Numbers:
Why it matters: This expanded indication gives oncologists a powerful new option earlier in the metastatic prostate cancer journey for HRR-mutated patients, potentially delaying disease progression significantly before castration resistance develops.
